NASDAQ:LMNXLuminex Stock Price, Forecast & News

$31.15

+0.01 (+0.03 %)

(As of 06/3/2020 03:21 PM ET)

Add

Compare

Today's Range

$30.60

Now: $31.15▼

$31.23

50-Day Range

$28.96

MA: $33.13▼

$38.83

52-Week Range

$17.34

Now: $31.15▼

$40.21

Volume23,258 shs

Average Volume955,685 shs

Market Capitalization$1.43 billion

P/E RatioN/A

Dividend Yield1.14%

Beta0.66

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Beat the Market (BTM) Rank^™

1.0 Analyst's Opinion

Consensus Rating
Luminex has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $26.50, Luminex has a potential downside of 14.9% from its current price of $31.15.
Amount of Analyst Coverage
Luminex has received no research coverage in the past 90 days.

2.0 Community Rank

Outperform Votes
Luminex has received 252 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Luminex has received 379 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Luminex has received 60.06% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote “Outperform” if you believe LMNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Leadership
Luminex is a leading dividend payer. It pays a dividend yield of 1.14%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Luminex has only been increasing its dividend for 2 years.
Dividend Sustainability
Based on EPS estimates, Luminex will have a dividend payout ratio of 94.74 % in the coming year. This indicates that Luminex may not be able to sustain their current dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Luminex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,411,274.00 in company stock.
Percentage Held by Insiders
Only 9.40% of the stock of Luminex is held by insiders.
Percentage Held by Institutions
80.71% of the stock of Luminex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Luminex are expected to grow by 123.53% in the coming year, from $0.17 to $0.38 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Luminex is -207.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Luminex is -207.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Luminex has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.51 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical & medical instruments

Sub-IndustryLife Sciences Tools & Services

SectorMedical

Current SymbolNASDAQ:LMNX

Previous Symbol

CUSIP55027E10

CIK1033905

Webwww.luminexcorp.com

Phone512-219-8020

Debt

Debt-to-Equity Ratio0.04

Current Ratio4.00

Quick Ratio2.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio183.24

P/E GrowthN/A

Sales & Book Value

Annual Sales$334.64 million

Price / Sales4.26

Cash Flow$0.42 per share

Price / Cash Flow74.06

Book Value$10.32 per share

Price / Book3.02

Profitability

EPS (Most Recent Fiscal Year)($0.21)

Net Income$-3,840,000.00

Net Margins-1.81%

Return on Equity-1.25%

Return on Assets-1.08%

Miscellaneous

Employees1,247

Outstanding Shares45,790,000

Market Cap$1.43 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableOptionable

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

Luminex (NASDAQ:LMNX) Frequently Asked Questions

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LMNX stock has increased by 14.9% and is now trading at $31.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Luminex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Luminex.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Luminex.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Monday, May, 4th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.02. The medical instruments supplier had revenue of $90.40 million for the quarter, compared to analysts' expectations of $82.30 million. Luminex had a negative net margin of 1.81% and a negative return on equity of 1.25%. The business's revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $0.07 EPS. View Luminex's earnings history.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a quarterly dividend on Tuesday, May 26th. Stockholders of record on Thursday, June 18th will be given a dividend of $0.09 per share on Thursday, July 9th. This represents a $0.36 annualized dividend and a yield of 1.16%. The ex-dividend date is Wednesday, June 17th. View Luminex's dividend history.

What guidance has Luminex issued on next quarter's earnings?

Luminex updated its FY 2020 After-Hours earnings guidance on Monday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $362 million, compared to the consensus revenue estimate of $350.06 million.

What price target have analysts set for LMNX?

2 equities research analysts have issued 12 month price objectives for Luminex's stock. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's share price to reach $26.50 in the next year. This suggests that the stock has a possible downside of 14.9%. View analysts' price targets for Luminex.

Has Luminex been receiving favorable news coverage?

News headlines about LMNX stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Luminex earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutLuminex.

Are investors shorting Luminex?

Luminex saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,890,000 shares, an increase of 7.4% from the April 30th total of 1,760,000 shares. Based on an average daily trading volume, of 649,800 shares, the short-interest ratio is currently 2.9 days. Approximately 4.5% of the shares of the stock are short sold. View Luminex's Current Options Chain.

Who are some of Luminex's key competitors?

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). View all competitors.

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), Verizon Communications (VZ), AbbVie (ABBV), American Express (AXP) and Micron Technology (MU).

Who are Luminex's key executives?

Luminex's management team includes the following people:

Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Who are Luminex's major shareholders?

Luminex's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.95%), State Street Corp (3.32%), Geode Capital Management LLC (1.44%), Bank of New York Mellon Corp (1.32%), Investment Management of Virginia LLC (0.98%) and Principal Financial Group Inc. (0.73%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir and Randall Myers. View institutional ownership trends for Luminex.

Which institutional investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Investment Management of Virginia LLC, Nuveen Asset Management LLC, Deutsche Bank AG, THB Asset Management, Morgan Stanley, Morgan Stanley, Dupont Capital Management Corp, and Russell Investments Group Ltd.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, and Randall Myers. View insider buying and selling activity for Luminex.

Which institutional investors are buying Luminex stock?

LMNX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Copeland Capital Management LLC, AQR Capital Management LLC, Wells Fargo & Company MN, BlackRock Inc., EAM Global Investors LLC, Martingale Asset Management L P, and Geode Capital Management LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir. View insider buying and selling activity for Luminex.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $31.15.

How big of a company is Luminex?

Luminex has a market capitalization of $1.43 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

What is Luminex's official website?

The official website for Luminex is www.luminexcorp.com.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff